Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
PCYC [NASD]
Pharmacyclics Inc.
Healthcare | Drug Manufacturers - Other | USA
financial highlights | statements
Index- P/E144.69 EPS (ttm)0.61 Insider Own18.70% Shs Outstand70.93M Perf Week-0.71%
Market Cap6.26B Forward P/E- EPS next Y-0.51 Insider Trans-1.35% Shs Float58.44M Perf Month3.97%
Income48.70M PEG904.30 EPS next Q-0.04 Inst Own69.10% Short Float3.69% Perf Quarter1.89%
Sales165.60M P/S37.81 EPS this Y835.30% Inst Trans0.96% Short Ratio2.92 Perf Half Y44.57%
Book/sh6.16 P/B14.33 EPS next Y43.30% ROA13.70% Target Price100.80 Perf Year117.82%
Cash/sh7.21 P/C12.25 EPS next 5Y0.16% ROE18.60% 52W Range40.65 - 95.85 Perf YTD52.75%
Dividend- P/FCF- EPS past 5Y30.00% ROI44.80% 52W High-7.92% Beta1.27
Dividend %- Quick Ratio11.20 Sales past 5Y- Gross Margin- 52W Low117.12% ATR3.72
Employees247 Current Ratio11.20 Sales Q/Q47.40% Oper. Margin30.00% RSI (14)56.00 Volatility2.63% 4.58%
OptionableYes Debt/Eq0.00 EPS Q/Q-284.20% Profit Margin29.40% Rel Volume0.46 Prev Close87.19
ShortableYes LT Debt/Eq0.00 EarningsMay 01 AMC Payout0.00% Avg Volume738.24K Price88.26
Recom2.30 SMA201.68% SMA507.51% SMA20023.56% Volume340,476 Change1.23%
12-Dec-12Reiterated Wedbush Outperform $93 → $110
24-Aug-12Initiated Stifel Nicolaus Hold
02-Aug-12Downgrade Needham Buy → Hold
17-May-12Reiterated Rodman & Renshaw Mkt Outperform $22 → $40
17-May-12Reiterated Needham Buy $23 → $32
21-Feb-12Upgrade RBC Capital Mkts Sector Perform → Outperform $15 → $34
09-Dec-11Downgrade RBC Capital Mkts Outperform → Sector Perform $15 → $15
09-Dec-11Downgrade Global Hunter Securities Buy → Neutral $15 → $15
07-Dec-11Initiated Rodman & Renshaw Mkt Outperform $20
11-Nov-11Resumed Needham Buy $14
20-Jun-11Reiterated RBC Capital Mkts Outperform $10 → $15
07-Jun-10Reiterated Wedbush Outperform $8 → $16
14-Apr-10Reiterated Roth Capital Buy $7 → $11
12-Mar-10Initiated Roth Capital Buy $7
12-Feb-10Downgrade BWS Financial Buy → Hold
29-Jan-10Initiated Merriman Buy
17-Feb-09Reiterated RBC Capital Mkts Outperform $4 → $2
13-Oct-08Upgrade BWS Financial Hold → Buy $2
03-Sep-08Upgrade RBC Capital Mkts Sector Perform → Outperform
17-Aug-07Upgrade BWS Financial Sell → Hold $2
18-Jun-13 10:21AM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
17-Jun-13 01:50AM  PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
01:38AM  InPlay: Pharmacyclics reports updated results of two Phase 2 Ibrutinib studies in patients with Mantle Cell Lymphoma or diffuse Large B-cell Lymphoma Briefing.com
16-Jun-13 06:00AM  Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma PR Newswire
14-Jun-13 10:35AM  Pharmacyclics' Recent Sell-Off Was Wrong: Here's Why We're Involved at Seeking Alpha
11-Jun-13 10:17AM  Acadia Pharmaceuticals Soars On Hedge Fund Investment at Motley Fool
10-Jun-13 12:51PM  Infinity Pharma's Safety Concerns: For Patient Investors, A Buying Opportunity at Seeking Alpha
10:51AM  Snatch PCYC 7.4% Cheaper Than Its Secondary? at Forbes
07:00AM  Winners And Losers in CLL at ASCO '13 at TheStreet
04-Jun-13 03:01PM  4 Stocks On The Verge Of Breaking Out! at Motley Fool
03-Jun-13 09:31AM  Ingram Micro Senior EVP Sells More Than 16K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
08:00AM  ASCO '13 Live Blog: Prepping for Monday Trading at TheStreet
02:01AM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
29-May-13 08:00AM  Making The Call: Pharmacyclics FDA Drug Approval Before Year End at TheStreet
26-May-13 08:25PM  Gilead Sciences' Move Into Cancer Drugs at Seeking Alpha
23-May-13 01:03PM  5 Stocks Raising The Drugs Industry Higher at TheStreet
09:31AM  PHARMACYCLICS INC Files SEC form 8-K, Amendment or Waiver to Code of Ethics EDGAR Online
22-May-13 03:50PM  FDA Designation for Synageva Candidate Zacks
21-May-13 07:00AM  2013 FDA Drug Approval Calendar at TheStreet
03:45AM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
19-May-13 06:30PM  Tackling Cancer: Leukemia's Biggest Current and Upcoming Players at Motley Fool
16-May-13 01:23PM  Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund: Investing in Health Care Innovation Wall Street Transcript
15-May-13 11:02PM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
07:09PM  With 'Cell Death' Drugs, Bristol-Myers May Win No Matter What at Forbes
06:00PM  ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up at TheStreet
06:00PM  ASCO '13 Preview: Gilead's Big Cancer Debut at TheStreet
12:24PM  Three Value-Presenting Stocks With Upgrades on Monday at Motley Fool
14-May-13 11:02PM  PHARMACYCLICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Submission of Matters to a Vote of EDGAR Online
13-May-13 03:53PM  Pharmacyclics Rises On Unusually High Volume (PCYC) at TheStreet +8.82%
03:06PM  3 Biotech Stocks Spiking With Big Volume at TheStreet
10-May-13 02:57PM  6 Superstars For Your Biotech Portfolio: John McCamant at Seeking Alpha +6.07%
11:44AM  Climbing the Wall of Worry at Motley Fool
07-May-13 01:58PM  Right Time To Buy This Pharmaceutical Company? at Motley Fool
10:14AM  PHARMACYCLICS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
04-May-13 04:43PM  2 Winners and 3 Losers from This Weeks Earnings Storm at Wall St. Cheat Sheet
03-May-13 10:18PM  Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential at Seeking Alpha
02-May-13 01:30PM  Wider-Than-Expected Loss at Pharmacyclics Zacks
11:08AM  David Amsellem, Managing Director and Senior Research Analyst at Piper Jaffray & Co., Interviews with The Wall Street Transcript: Alternative Dosage Forms Create Barriers Against Competition in Generics Wall Street Transcript
01-May-13 09:40PM  Pharmacyclics Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha -6.44%
07:37PM  Pharmacyclics Earnings: Everything You Must Know Now at Wall St. Cheat Sheet
06:37PM  Pharmacyclics posts bigger 1Q loss on stock costs AP
06:20PM  Can This Biotech Soar Again? at Motley Fool
04:05PM  Pharmacyclics Reports First Quarter 2013 Results PR Newswire
09:17AM  PHARMACYCLICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
07:07AM  Q3 2013 Pharmacyclics Earnings Release - After Market Close CCBN
28-Apr-13 01:54PM  Tracking Cash Inflows: A Good Method to Locate Investment Opportunities at Motley Fool
26-Apr-13 11:48AM  Ramin Najafi, Founder, Chairman and CEO of NovaBay Pharmaceuticals, Inc. (NBY), Interviews with The Wall Street Transcript Wall Street Transcript
25-Apr-13 04:30PM  FDA Designation for Merck Candidate Zacks
24-Apr-13 04:05PM  Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call PR Newswire
23-Apr-13 05:30PM  Abbott - Epizyme Collaborate Zacks
04:41PM  Pharmacyclics Larger Than S&P 500 Component Interpublic Group of Companies at Forbes
01:54PM  Are These Billion-Dollar Biotechs Overvalued? at Motley Fool
19-Apr-13 02:00PM  PCYC Completes RESONATE Enrollment Zacks
18-Apr-13 11:02PM  PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
04:15PM  Pharmacyclics completes enrollment of phase 3 study for leukemia treatment theflyonthewall.com
04:10PM  InPlay: Pharmacyclics completes enrollment of First Phase III ibrutinib CLL study - RESONATE and announces completion of enrollment of Phase II ibrutinib MCL study - SPARK Briefing.com
04:08PM  Mega-Hedge Fund Focusing on the Life Sciences at Motley Fool
04:05PM  Pharmacyclics Completes Enrollment of First Phase III Ibrutinib CLL Study - RESONATE and Announces Completion of Enrollment of Phase II Ibrutinib MCL Study - SPARK PR Newswire
17-Apr-13 02:20PM  Tackling Cancer: Non-Hodgkin Lymphoma's Biggest Current & Upcoming Players at Motley Fool
16-Apr-13 08:37PM  These Cutting-Edge Science Stocks Are Soaring at Motley Fool
15-Apr-13 04:00PM  Health Care's Biggest Movers and Shakers at Motley Fool
11:54AM  Pharmacyclics Earns 4th Milestone Zacks
11-Apr-13 02:19PM  Quest Diagnostics shares climb on glowing words from Goldman at MarketWatch
12:26PM  Quest Diagnostics shares climb on glowing words from Goldman at MarketWatch
09:54AM  A "Breakthrough" May Be on the Way for Breast Cancer Patients at Motley Fool
09:31AM  PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
06:31AM  InPlay: Pharmacyclics triggers fourth milestone payment for enrollment of 5th patient in frontline Phase III CLL study Briefing.com
06:30AM  Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study PR Newswire
10-Apr-13 09:44AM  FDA's Breakthrough Therapy Designation More Bling Than Bite at Motley Fool
09-Apr-13 05:01PM  Pharmacyclics Incorporated (PCYC): Drugs' Featured Daily Laggard at TheStreet
08-Apr-13 01:00PM  InPlay: Pharmacyclics reports Phase II ibrutinib monotherapy study shows CLL patients achieved rapid and sustainable disease control irrespective of age or high risk prognostic factor Briefing.com
01:00PM  Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor PR Newswire
10:27AM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
10:15AM  Analysts: Yum Brands Get a Bird Flu Warning and 2 New Opinions Investors Must Read Now at Wall St. Cheat Sheet
08:50AM  InPlay: Pharmacyclics trading up 5% following third breakthrough therapy designation for Ibrutinib from the FDA (see 6:30) Briefing.com
06:35AM  Pharmacyclics says FDA grants Breakthrough Therapy Designation for ibrutinib theflyonthewall.com
06:30AM  InPlay: Pharmacyclics announces third breakthrough therapy designation for Ibrutinib from the FDA Briefing.com
06:30AM  Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration PR Newswire
06-Apr-13 12:15PM  Health Policy Is in Flux, and So Are 2 Health Funds at New York Times
05-Apr-13 11:37PM  The Wild Story Behind A Promising Experimental Cancer Drug at Forbes
05:29PM  The 9 Levels Of Healthcare / Biotechnology And Who Should Invest - Part 1 at Seeking Alpha
05:00AM  Pharmacyclics Incorporated Stock Downgraded (PCYC) at TheStreet
26-Mar-13 03:54PM  4 Healthcare Stock Stories for Tuesday Investment Wellness at Wall St. Cheat Sheet
25-Mar-13 10:03AM  Analysts: Pharmacyclics Presents Buying Chance and 3 New Opinions Investors Must Know Now at Wall St. Cheat Sheet
23-Mar-13 08:30AM  3 Horrendous Health-Care Stocks This Week at Motley Fool
22-Mar-13 06:04PM  Nasdaq stocks posting largest percentage decreases AP
01:17PM  Nasdaq stocks posting largest percentage decreases AP
21-Mar-13 06:05PM  Nasdaq stocks posting largest percentage decreases AP -8.43%
20-Mar-13 05:37PM  Under-the-Radar Hedge Fund Focusing on Pharma at Motley Fool
09:14AM  New Stock Coverage: Has Whole Foods Become Spoiled? at Minyanville
19-Mar-13 05:01PM  Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Laggard at TheStreet
01:04PM  INCY, PCYC, EW And A, 4 Health Care Stocks Pushing The Sector Lower at TheStreet
18-Mar-13 12:02PM  Which Medical Device Companies Have the Most Upside Potential in 2013? An Expert Equity Analyst Discusses Renal Denervation and Transcatheter Heart Valves, as well as the European Slowdown Wall Street Transcript
14-Mar-13 04:19PM  PHARMACYCLICS INC Files SEC form 8-K, Other Events EDGAR Online
11-Mar-13 03:28PM  Pharmacyclics to Sell Shares Zacks
01:19PM  Snatch PCYC Even Cheaper Than Its Secondary? at Forbes
08-Mar-13 05:25PM  PHARMACYCLICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements EDGAR Online
05:01PM  Pharmacyclics Incorporated (PCYC): Today's Featured Health Care Laggard at TheStreet
05:00PM  Finding the Next Home Run Stock at Motley Fool
12:45PM  Nasdaq clues suggest more upward valuation at MarketWatch
Pharmacyclics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of small-molecule drugs for the treatment of cancer and immune mediated diseases. Its principal products candidates in clinical development include ibrutinib, which is under multiple Phase III studies in hematologic malignancies; a BTK inhibitor lead optimization program targeting anti-inflammatory and autoimmune indications; PCI-27483, an inhibitor of Factor VIIa that is in phase II clinical trial for the treatment of pancreatic cancer; and a HDAC inhibitor abexinostat, which is in Phase I and II clinical trials for the treatment of solid tumors and hematological malignancies. The company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It has a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ibrutinib and other structurally related compounds; collaboration and license agreement with Les Laboratoires Servier to develop and commercialize abexinostat; and license agreement with Novo Nordisk A/S to research and develop PCI-27483. Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shearer Scott TVP, Global QualityJun 06Option Exercise30.4618,750571,12518,750Jun 06 06:46 PM
Shearer Scott TVP, Global QualityJun 06Sale85.1718,7501,596,9940Jun 06 06:46 PM
McGreivy JesseVP, Clinical ScienceMay 31Option Exercise37.8614,479548,10314,479May 31 08:02 PM
Love Richard BVP and General CounselMay 31Option Exercise32.388,000259,0408,000May 31 08:03 PM
Tan HeowChief of Technical OperationsMay 31Option Exercise27.055,000135,2505,237May 31 08:06 PM
Hemmi GregoryVP Chemical OperationsMay 31Option Exercise2.7050,000135,17974,236May 31 08:15 PM
Hemmi GregoryVP Chemical OperationsMay 31Sale91.9650,0004,598,11524,236May 31 08:15 PM
Tan HeowChief of Technical OperationsMay 31Sale91.845,237480,9610May 31 08:06 PM
Love Richard BVP and General CounselMay 31Sale89.008,000712,0000May 31 08:03 PM
McGreivy JesseVP, Clinical ScienceMay 31Sale91.1314,4791,319,5100May 31 08:02 PM
Buggy Joseph JVP, ResearchFeb 11Option Exercise0.8612,00010,32018,701Feb 11 07:19 PM
Buggy Joseph JVP, ResearchFeb 11Sale69.9712,000839,6666,701Feb 11 07:19 PM
Loury David JChief Scientific OfficerFeb 05Option Exercise2.7620,00055,20020,325Feb 05 07:08 PM
Loury David JChief Scientific OfficerFeb 05Sale70.5820,0001,411,510325Feb 05 07:08 PM
McGreivy JesseVP, Clinical ScienceJan 17Sale67.2958339,2290Jan 18 06:37 PM
Hemmi GregoryVP Chemical OperationsJan 11Option Exercise3.695,00018,47127,992Jan 11 07:30 PM
Hemmi GregoryVP Chemical OperationsJan 11Sale67.115,000335,55022,992Jan 11 07:30 PM
Loury David JChief Scientific OfficerJan 09Sale66.3010,531698,205325Jan 10 03:15 PM
Loury David JChief Scientific OfficerJan 08Option Exercise4.1610,00041,60010,325Jan 08 07:15 PM
Fardis MariaEVP, Operations and AlliancesJan 08Sale65.002,500162,500976Jan 09 07:05 PM
Loury David JChief Scientific OfficerJan 08Sale64.7010,000647,000325Jan 08 07:15 PM
Fardis MariaEVP, Operations and AlliancesJan 07Option Exercise6.843,50023,9406,976Jan 07 08:23 PM
Fardis MariaEVP, Operations and AlliancesJan 07Sale64.203,500224,7003,476Jan 07 08:23 PM
van den Broek RichardDirectorDec 31Sale58.507,171419,476108,445Jan 02 02:20 PM
van den Broek RichardDirectorDec 28Sale57.9818,3541,064,125108,445Dec 28 04:38 PM
Hemmi GregoryVP Chemical OperationsDec 27Option Exercise6.0412,90077,88335,892Dec 27 06:22 PM
van den Broek RichardDirectorDec 27Sale58.0211,931692,239126,799Dec 28 04:38 PM
Hemmi GregoryVP Chemical OperationsDec 27Sale59.2012,900763,72522,992Dec 27 06:22 PM
Hemmi GregoryVP Chemical OperationsDec 26Option Exercise4.4710044723,092Dec 27 06:22 PM
Hemmi GregoryVP Chemical OperationsDec 26Sale59.001005,90022,992Dec 27 06:22 PM
Loury David JChief Scientific OfficerDec 20Option Exercise4.1639,469164,19139,794Dec 21 07:09 PM
Loury David JChief Scientific OfficerDec 20Sale61.1239,4692,412,274325Dec 21 07:09 PM
Erdtmann Rainer MVP, IR Education TrainingDec 18Option Exercise0.9159,55854,19887,043Dec 18 07:05 PM
Erdtmann Rainer MVP, IR Education TrainingDec 18Sale62.4859,5583,721,09227,485Dec 18 07:05 PM
Buggy Joseph JVP, ResearchDec 17Option Exercise0.7550,00037,50056,701Dec 17 07:10 PM
Erdtmann Rainer MVP, IR Education TrainingDec 17Option Exercise0.9134,44231,34261,927Dec 18 07:05 PM
Buggy Joseph JVP, ResearchDec 17Sale62.1450,0003,106,8406,701Dec 17 07:10 PM
Erdtmann Rainer MVP, IR Education TrainingDec 17Sale62.7334,4422,160,69827,485Dec 18 07:05 PM
open in yahoo | open in reuters | open in google